Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Hideaki Shiraishi, Yutaka Fujiwara, Takanori Kakuya, Koji Tsuta, Noriko Motoi, Nami Miura, Yukio Watabe, Shun Ichi Watanabe, Rintaro Noro, Kengo Nagashima, Wilber Huang, Tesshi Yamada, Hisao Asamura, Yuichiro Ohe, Kazufumi Honda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

Original languageEnglish
Pages (from-to)721-731
Number of pages11
JournalBiomarkers in Medicine
Volume11
Issue number9
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Actinin
Chemotherapy
Biomarkers
Adjuvant Chemotherapy
Proteins
Hazards
Immunohistochemistry
Observation
Survival
Combination Drug Therapy
Platinum
Adenocarcinoma of lung
Clinical Trials

Keywords

  • actinin-4 (ACTN4)
  • adjuvant chemotherapy
  • predictive biomarker

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. / Shiraishi, Hideaki; Fujiwara, Yutaka; Kakuya, Takanori; Tsuta, Koji; Motoi, Noriko; Miura, Nami; Watabe, Yukio; Watanabe, Shun Ichi; Noro, Rintaro; Nagashima, Kengo; Huang, Wilber; Yamada, Tesshi; Asamura, Hisao; Ohe, Yuichiro; Honda, Kazufumi.

In: Biomarkers in Medicine, Vol. 11, No. 9, 01.09.2017, p. 721-731.

Research output: Contribution to journalArticle

Shiraishi, H, Fujiwara, Y, Kakuya, T, Tsuta, K, Motoi, N, Miura, N, Watabe, Y, Watanabe, SI, Noro, R, Nagashima, K, Huang, W, Yamada, T, Asamura, H, Ohe, Y & Honda, K 2017, 'Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma', Biomarkers in Medicine, vol. 11, no. 9, pp. 721-731. https://doi.org/10.2217/bmm-2017-0150
Shiraishi, Hideaki ; Fujiwara, Yutaka ; Kakuya, Takanori ; Tsuta, Koji ; Motoi, Noriko ; Miura, Nami ; Watabe, Yukio ; Watanabe, Shun Ichi ; Noro, Rintaro ; Nagashima, Kengo ; Huang, Wilber ; Yamada, Tesshi ; Asamura, Hisao ; Ohe, Yuichiro ; Honda, Kazufumi. / Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. In: Biomarkers in Medicine. 2017 ; Vol. 11, No. 9. pp. 721-731.
@article{7dd9a84ce9884b49875ca0833714824e,
title = "Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma",
abstract = "Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.",
keywords = "actinin-4 (ACTN4), adjuvant chemotherapy, predictive biomarker",
author = "Hideaki Shiraishi and Yutaka Fujiwara and Takanori Kakuya and Koji Tsuta and Noriko Motoi and Nami Miura and Yukio Watabe and Watanabe, {Shun Ichi} and Rintaro Noro and Kengo Nagashima and Wilber Huang and Tesshi Yamada and Hisao Asamura and Yuichiro Ohe and Kazufumi Honda",
year = "2017",
month = "9",
day = "1",
doi = "10.2217/bmm-2017-0150",
language = "English",
volume = "11",
pages = "721--731",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

AU - Shiraishi, Hideaki

AU - Fujiwara, Yutaka

AU - Kakuya, Takanori

AU - Tsuta, Koji

AU - Motoi, Noriko

AU - Miura, Nami

AU - Watabe, Yukio

AU - Watanabe, Shun Ichi

AU - Noro, Rintaro

AU - Nagashima, Kengo

AU - Huang, Wilber

AU - Yamada, Tesshi

AU - Asamura, Hisao

AU - Ohe, Yuichiro

AU - Honda, Kazufumi

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

AB - Aim: Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. Materials & methods: We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups. Results: A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR]: 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR: 0.926; p = 0.876) in the latter. Conclusion: This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.

KW - actinin-4 (ACTN4)

KW - adjuvant chemotherapy

KW - predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=85029783329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029783329&partnerID=8YFLogxK

U2 - 10.2217/bmm-2017-0150

DO - 10.2217/bmm-2017-0150

M3 - Article

C2 - 28658966

AN - SCOPUS:85029783329

VL - 11

SP - 721

EP - 731

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 9

ER -